Also trades as: RP.V (TSXV) · $vol 0M
REPCF OTC
RepliCel Life Sciences Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
YTD: +0.0%
1Y: +0.0%
3Y: -98.6%
5Y: -99.6%
$0.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$354K
+0.0% ▲
5Y CAGR: +0.0%
Gross Profit
$354K
+0.4% ▲
5Y CAGR: +0.0%
Operating Income
-$360K
+74.0% ▲
Net Income
-$97K
+68.8% ▲
EPS (Diluted)
$-0.00
+69.8% ▲
EBITDA
-$359K
+74.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $354K | $354K | $354K | $354K | $354K |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $0 | $0 | $1K | $0 |
| Gross Profit | $354K | $354K | $354K | $352K | $354K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 99.6% | 100.0% |
| R&D Expenses | $819K | $1M | $624K | $526K | $113K |
| SG&A Expenses | $885K | $2M | $1M | $1M | $601K |
| Operating Expenses | $2M | $3M | $2M | $2M | $714K |
| Operating Income | -$1M | -$2M | -$1M | -$1M | -$360K |
| Operating Margin | -375.4% | -649.6% | -393.8% | -391.8% | -101.8% |
| Interest Expense | $0 | $6K | $7K | $149K | $114K |
| Income Before Tax | -$2M | -$4M | -$743K | -$312K | -$97K |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$2M | -$4M | -$743K | -$312K | -$97K |
| Net Margin | -446.7% | -1151.4% | -210.0% | -88.2% | -27.5% |
| EPS (Diluted) | $-0.06 | $-0.13 | $-0.02 | $-0.01 | $-0.00 |
| EBITDA | -$2M | -$4M | -$736K | -$1M | -$359K |
| Shares Outstanding | 27M | 32M | 38M | 59M | 62M |